Astria
Release Forms:
The composition of 1 tablet:
- active substance: desloratsdine;
- 1 tablet contains desloratadine 5 mg
- excipients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, corn starch, talc, a mixture of carnauba and white wax; coating: hypromellose, polyethylene glycol (macrogol) 6000, titanium dioxide (E171) indigo (E132).
10 tablets in a blister
Indications.
Elimination of symptoms associated with allergic rhinitis and urticaria.
Contraindications.
Hypersensitivity to the active substance or to any of the excipients or to loratadine.
Adults and children over 12 years of age are prescribed 1 tablet 1 time per
day regardless of food intake to eliminate the symptoms associated with
allergic rhinitis (including intermittent and persistent allergic rhinitis)
rhinitis) and urticaria.
Treatment of intermittent allergic rhinitis (symptoms less than 4
days per week or less than 4 weeks) must be carried out taking into account
history: discontinue after resolution of symptoms and resume after
their recurrence. With persistent allergic rhinitis (presence
symptoms more than 4 days a week or more than 4 weeks) is necessary
continue treatment throughout the period of contact with the allergen.